We are live on ! Find out more
AC

Aisling Capital Portfolio holdings

AUM $45.3M
1-Year Est. Return 15.24%
This Fund
S&P 500
This Quarter Est. Return
-8.55%
1 Year Est. Return
-15.24%
3 Year Est. Return
+386.13%
5 Year Est. Return
+981.36%
10 Year Est. Return
–
AUM
$499M
AUM Growth
-$80.4M
Cap. Flow
+$16.1M
Cap. Flow %
3.22%
Top 10 Hldgs %
79.05%
Holding
23
New
1
Increased
1
Reduced
2
Closed
1

Top Buys

Rank Stock Value
1
VRAY
ViewRay, Inc.
VRAY
+$32.1M
2
DERM
Dermira, Inc.
DERM
+$3.68M

Top Sells

Rank Stock Value
1
CEMP
Cempra, Inc.
CEMP
+$18.1M
2
ROKA
Sorrento Tech, Inc. Common Stock
ROKA
+$47.8K
3
SRNE
Sorrento Therapeutics, Inc.
SRNE
+$34K

Sector Composition

Rank Sector Weight
1 Healthcare 67.95%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LOXO
1
DELISTED
Loxo Oncology, Inc
LOXO
$104M 20.78%
3,796,362
– –
ZLTQ
2
DELISTED
ZELTIQ Aesthetics, Inc.
ZLTQ
$57.1M 11.44%
2,103,528
– –
AIMT
3
DELISTED
Aimmune Therapeutics
AIMT
$40.5M 8.12%
2,990,000
– –
ASXC
4
DELISTED
Asensus Surgical, Inc.
ASXC
$35.4M 7.09%
641,217
– –
VRAY
5
DELISTED
ViewRay, Inc.
VRAY
$32.1M 6.43%
+7,461,923
New +$32.1M
ADMA icon
6
ADMA Biologics
ADMA
$1.99B
$29.2M 5.85%
3,608,171
– –
TTOO
7
DELISTED
T2 Biosystems, Inc
TTOO
$27.9M 5.59%
566
– –
ESPR
8
DELISTED
Esperion Therapeutics
ESPR
$27.7M 5.54%
1,637,125
– –
CEMP
9
DELISTED
Cempra, Inc.
CEMP
$20.9M 4.19%
1,193,060
-1,000,000
-46% -$18.1M
DERM
10
DELISTED
Dermira, Inc.
DERM
$20.1M 4.02%
970,823
+150,000
+18% +$3.68M
CTLT
11
DELISTED
CATALENT, INC.
CTLT
$19.1M 3.82%
715,673
– –
AGRX
12
DELISTED
Agile Therapeutics
AGRX
$18.5M 3.71%
1,492
– –
ARAV
13
DELISTED
Aravive, Inc. Common Stock
ARAV
$18.3M 3.66%
379,928
– –
CDTX
14
DELISTED
Cidara Therapeutics
CDTX
$12.9M 2.59%
50,973
– –
CYNA
15
DELISTED
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
$12.2M 2.43%
1,021,381
– –
PRTK
16
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$10.4M 2.07%
682,680
– –
XENT
17
DELISTED
Intersect ENT, Inc
XENT
$6.65M 1.33%
350,000
– –
CMRX
18
DELISTED
Chimerix, Inc.
CMRX
$2.42M 0.48%
472,943
– –
PTX
19
DELISTED
Pernix Therapeutics Holdings, Inc.
PTX
$2.11M 0.42%
201,000
– –
EVAR
20
DELISTED
Lombard Medical, Inc.
EVAR
$931K 0.19%
886,363
– –
ROKA
21
DELISTED
Sorrento Tech, Inc. Common Stock
ROKA
$354K 0.07%
51,292
-5,980
-10% -$47.8K
SRNE
22
DELISTED
Sorrento Therapeutics, Inc.
SRNE
– –
-3,855
Closed -$34K

Similar funds

SCPM
Sagard Capital Partners Management New York $46.7M AUM 23.43% 1-Year Est. Return
ZIM
ZPR Investment Management Orange City, Florida $46.8M AUM 2.45% 1-Year Est. Return
ACP
Aquiline Capital Partners New York $46.9M AUM 5.65% 1-Year Est. Return
INL
IPC/NYCG LLC New York $43.3M AUM 61.41% 1-Year Est. Return
CP
Clover Partners Dallas, Texas $43.1M AUM 4.09% 1-Year Est. Return
SAM
Sheffield Asset Management Chicago, Illinois $48.1M AUM 12.96% 1-Year Est. Return
JCM
Julex Capital Management Wellesley, Massachusetts $42.4M AUM 9.78% 1-Year Est. Return
GX
Greylock XII Menlo Park, California $51.9M AUM 11.52% 1-Year Est. Return

Aisling Capital's Q1 2016 Portfolio in Review

As of Q1 2016, Aisling Capital held 23 positions worth $499M, down 14% from $580M the previous quarter. Its ten largest holdings account for 79% of the portfolio.

Aisling Capital deployed $16.1M of net new capital in Q1 2016, opening 1 new position and adding to 1 existing holding. Its largest new stake was ViewRay, Inc.: 7,461,923 shares worth $32.1M.

By sector, the portfolio is most concentrated in Healthcare at 68% of assets, down from 71% a quarter earlier.

On the sell side, the largest reduction was Cempra, Inc., an estimated $18.1M trimmed.

  • Aisling Capital's largest Q1 2016 buy was ViewRay, Inc.: 7,461,923 shares worth $32.1M.
  • Aisling Capital added most to Dermira, Inc. in Q1 2016, an estimated $3.68M increase.
  • Aisling Capital's biggest Q1 2016 reduction was Cempra, Inc., cutting an estimated $18.1M.
  • Aisling Capital fully exited Sorrento Therapeutics, Inc. in Q1 2016, selling an estimated $34K.
  • Aisling Capital's ten largest holdings make up 79% of its $499M portfolio in Q1 2016.
  • Aisling Capital opened 1 new position and closed 1 in Q1 2016.
  • Aisling Capital's portfolio value fell 14% quarter-over-quarter to $499M.

Based on Aisling Capital's 13F filing for Q1 2016, filed 13 May 2016.